Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin, Erbitux Prices Invite Price Controls, Former NCI Deputy Says In Editorial

This article was originally published in The Pink Sheet Daily

Executive Summary

The prices set by Genentech and Bristol-Myers Squibb for their recently launched colorectal cancer therapies are an invitation to impose price controls, former Memorial-Sloan Kettering Cancer Center Physician-in-Chief Robert Wittes, MD, wrote in an editorial published by the Washington Post June 15
Advertisement

Related Content

Genzyme's Clolar Treatment Priced At $90,000 For An Average Patient
Genzyme's Clolar Treatment Priced At $90,000 For An Average Patient
Bristol/Imclone Review Erbitux Pricing For Chronic Care Patients
Bristol/Imclone Review Erbitux Pricing For Chronic Care Patients
CMS’ Off-Label Coverage Decision For Colorectal Cancer Drugs Could Include Registries
CMS’ Off-Label Coverage Decision For Colorectal Cancer Drugs Could Include Registries
Colorectal Cancer Drug Costs May Force Rationing – ASCO Presentation
Colorectal Cancer Drug Costs May Force Rationing – ASCO Presentation

Topics

Advertisement
UsernamePublicRestriction

Register

PS059675

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel